Compass Pathways Plc Q3 FY2024 earnings call

Kabir Nath addressed the delay in disclosing COMP360 trial data, updating COMP005 6-week data to Q2 2025 and COMP006 data to H2 2026 due to trial complexities. Lori Englebert discussed commercial preparation, including billing codes, DEA rescheduling, KOL interactions, and health economics research. Teri Loxam provided financial updates, noting cash used in operations, Q4 2024 guidance, cash position, and workforce reduction to preserve cash. Mike Gold highlighted drug development experience and site support, while Guy Goodwin commented on trial eligibility and relapse criteria.

COMP005 6-week data disclosure moved to Q2 2025. COMP006 data now expected in H2 2026. Q4 2024 net cash used in operations expected between $37M and $43M. Full year 2024 cash used in operations预计 between $114M and $120M. Workforce reduction planned to preserve cash, with cash runway funding operations into 2026.

Trial complexity may affect enrollment and data disclosure. Challenges in maintaining blinding in COMP006. Regulatory uncertainties for new drug class. Workforce reduction could impact operations.

Q: Was your decision to move the top line readout made after additional FDA correspondence or a face-to-face meeting?

A: It was a COMPASS decision out of an abundance of caution after observing the Lykos process.

Q: How do the potential complexities in trial recruitment impact COMP360's real-world use?

A: Clinical trial setting differs from commercial, but learnings inform commercialization; focus on physician education and patient flow optimization.

Q: Are enrollment patterns and washout of antidepressant meds a challenge?

A: >90% successful washout rate, no logistical obstacle; reluctance from investigators but not a problem in trials.

Q: What's the impact of the 006 timing shift on cash and enrollment?

A: Guidance incorporates conservatism, efforts to accelerate enrollment in Europe and with experienced 005 sites rolling into 006.

Q: What's needed between data readouts and launch?

A: Educate on TRD and COMP360, reschedule states for DEA approval, optimize patient flow, ensure formulary access.

Q: Eligibility for retreatment and relapse definition?

A: Criteria based on MADRS, no difference between phases; patients can stay on antidepressants in Part C.

Q: How is suicidal ideation imbalance defined?

A: DSMB independent, clinical interpretation based on case severity.

Q: NDA submission and AdCom for COMP360?

A: Need data from both trials, expect AdCom; focus on clinically relevant effects in TRD trials.

Q: Dropout rates and enrollment adjustments?

A: Attrition below plan, no sample size adjustments; focus on accelerating recruitment and retention.

Q: 005 data announcement and 006 implications?

A: Always guided to release 005 6-week data; 006 design preserves blinding to minimize unblinding risk.

Q: Does the Phase III program provide enough commercial firepower for dosing schedule?

A: Phase III data provides important info for pricing and payer discussions.